 |
|
|
| |
Real-World Use of Long-Acting Cabotegravir + Rilpivirine in People with HIV with Detectable Viral Loads at Initiation: Findings from the OPERA® Cohort
|
| |
| |
Ricky K. Hsu
AHF & NYU Langone Health, New York, NY, USA
2 comments during Q&A that they were concerned that these failures might develop INSTI resistance and lose the class. "Limit use to those at severe risk for advanced HIV or mortality".
|
| |
|
|
|
|
|
